SELLAS Life Sciences announced a positive review of the ongoing Phase 3 REGAL clinical trial of galinpepimut-S in acute myeloid leukemia. The Independent Data Monitoring Committee, IDMC, performed a routine, prespecified risk-benefit assessment of unblinded data from the study and has recommended that the trial continue without modifications. The IDMC has further recommended to meet again within Q3 2023 and endorsed all clinical trial initiatives SELLAS has undertaken to advance GPS in the REGAL study, including the addition of clinical sites in China. "This positive IDMC review marks another significant milestone in GPS development and builds on the favorable profile of our study drug, galinpepimut-S," said Angelos Stergiou, MD, ScD h.c., President and Chief Executive Officer of SELLAS. "Enrollment continues in our global Phase 3 REGAL registrational study, which currently remains on track for interim analysis by the end of 2023 or early 2024."
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on SLS:
- SELLAS Life Sciences Independent Data Monitoring Committee Recommends Galinpepimut-S REGAL Trial to Continue as Planned
- SELLAS Life Sciences Reports Full Year 2022 Financial Results and Provides Business Update
- SELLAS Announces Publication of Positive GPS Clinical Data in Ovarian Cancer in Peer Reviewed Journal
- Sellas Life announces publication of GPS clinical data in ovarian cancer
- SELLAS Life Sciences Announces Pricing of $20.0 Million Underwritten Public Offering